戻る Agenda
Module 2: Candidate Identification/Preclinical Testing
Session Chair(s)
Stephen V. O'Quinn, PHARMD
President
Perissos, Inc., United States
- Discovery and Preclinical Phase for Development Programs – Key Players
- Market Assessment – Unmet Need and Commercial Valuation of Investigational Products
- Discovery Activities and Criteria for Nomination for Development
- API for Small Molecules
- Synthesis of Monoclonal Antibodies
- Preclinical Requirements to Support Phase 1
- Biomarkers, Surrogate Markers, and Companion Diagnosis
- Preparation for Phase 1